Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tax-Nazo: Neoadjuvant Docetaxel and Cisplatin in Nasopharyngeal Carcinoma
NCT00772681Phase 4Completed
- Sponsor
- Sanofi
- Start
- Oct 2004
- Primary completion
- Mar 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of docetaxel in nasopharyngeal carcinoma (NPC), sponsored by Sanofi. Primary endpoint: Complete Response Rate. Started Oct 2004; status: completed.
02
Drugs
docetaxel
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT00772681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00772681.